The European Pharmacopoeia Monograph 0478—Tablets is a cornerstone of pharmaceutical regulation in Europe and beyond. It goes far beyond a simple definition to provide a detailed, legally binding framework covering a tablet's entire lifecycle, from its design and manufacture to its final quality control.
Dissolution testing evaluates the rate at which the API is released from the tablet matrix into a liquid medium, simulating human physiological conditions. This is a critical surrogate marker for in vivo drug absorption and bioavailability. Modified-release and gastro-resistant tablets require highly specialized dissolution profiles (e.g., testing in acid medium followed by a buffer change). C. Disintegration (2.9.1)
This article provides an exhaustive technical breakdown of , covering its scope, analytical requirements (disintegration, dissolution, uniformity), official interpretation, and common pitfalls in Quality Control (QC) laboratories.
According to the , tablets are defined as solid preparations containing a single dose of one or more active substances . European Pharmacopoeia -ph. Eur.- Monograph Tablets -0478-
The European Pharmacopoeia (Ph. Eur.) is a publication that contains a set of monographs and general chapters that describe the official standards for medicines in Europe. The Ph. Eur. is published by the European Directorate for the Quality of Medicines & Healthcare (EDQM), which is a part of the Council of Europe. The Ph. Eur. is recognized as a standard for the quality of medicines in many countries, including all European Union member states.
More recent updates continued this evolution. Ph. Eur. Supplement 10.6, adopted by the Ph. Eur. Commission in November 2020, included further revisions to the general chapter .
: Designed to dissolve in water with the release of carbon dioxide. This is a critical surrogate marker for in
The monograph is strictly designated for .
The monograph specifies the test methods that must be used to evaluate tablets, including:
Monograph 0478 does not specify which chemical identity test to use (that is left to the individual active substance monograph). However, it mandates that the must be capable of distinguishing the tablet from placebo. Disintegration (2
The monograph defines tablets as solid pharmaceutical preparations, each containing a single dose of one or more active pharmaceutical ingredients (APIs). They are primarily manufactured through the compression of uniform volumes of particles or alternative technologies like extrusion, molding, or freeze-drying. Applicability Limitations
Measures the weight lost when tablets are tumbled in a rotating drum. A loss of less than 1% is generally required.